Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Clinical trial NCT00877110 · COMPLETED
Trial details
- NCT number
- NCT00877110
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-04-02
- Primary completion
- 2019-01-07
- Enrollment
- 71
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.